Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) EBIT (2020 - 2025)

Historic EBIT for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to -$35.3 million.

  • Janux Therapeutics' EBIT rose 164.89% to -$35.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$144.3 million, marking a year-over-year decrease of 6785.09%. This contributed to the annual value of -$98.8 million for FY2024, which is 3544.58% down from last year.
  • Latest data reveals that Janux Therapeutics reported EBIT of -$35.3 million as of Q3 2025, which was up 164.89% from -$45.1 million recorded in Q2 2025.
  • Janux Therapeutics' EBIT's 5-year high stood at -$2.3 million during Q1 2021, with a 5-year trough of -$45.1 million in Q2 2025.
  • In the last 5 years, Janux Therapeutics' EBIT had a median value of -$18.0 million in 2022 and averaged -$20.4 million.
  • Per our database at Business Quant, Janux Therapeutics' EBIT crashed by 76807.32% in 2021 and then skyrocketed by 3338.15% in 2024.
  • Over the past 5 years, Janux Therapeutics' EBIT (Quarter) stood at -$13.5 million in 2021, then tumbled by 35.4% to -$18.3 million in 2022, then grew by 11.66% to -$16.1 million in 2023, then crashed by 79.85% to -$29.0 million in 2024, then decreased by 21.46% to -$35.3 million in 2025.
  • Its EBIT was -$35.3 million in Q3 2025, compared to -$45.1 million in Q2 2025 and -$34.9 million in Q1 2025.